CEN Biotech, Inc. is a global holding company—dedicated to identifying and developing alternative approaches to business opportunities in diversified, yet related industries. With core operations focused on North America, Eastern Europe and China, CEN Biotech is continually looking to develop its dynamic and unique businesses, by seeking to leverage exclusive relationships with governments and private enterprises, around the world. In addition to CEN’s focus on improving the health and wellness of people, CEN also has proprietary technologies, which it believes has widespread commercial application in the digital media and data aggregation sectors.
Company profile
Ticker
CENBF
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Eastern Starr Biotech, Inc. • Clear Com Media, Inc. ...
Latest filings (excl ownership)
15-12G
Securities registration termination
12 Apr 23
NT 10-K
Notice of late annual filing
6 Apr 23
8-K
Entry into a Material Definitive Agreement
29 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
CEN Biotech Inc. Announces the Pending Launch of WordPresto
16 Sep 22
8-K
Regulation FD Disclosure
7 Sep 22
8-K
Entry into a Material Definitive Agreement
31 Aug 22
10-Q
2022 Q2
Quarterly report
22 Aug 22
NT 10-Q
Notice of late quarterly filing
15 Aug 22
8-K
Entry into a Material Definitive Agreement
20 Jul 22
Latest ownership filings
4
Rick Leigh Purdy
13 Apr 22
3
Lawrence Lehoux
21 Jul 21
SC 13D/A
Tarrabain Alex
25 Jun 21
4
Alex Tarrabain
25 Jun 21
SC 13D
Payne Brian
15 Jun 21
SC 13D
Chaaban Bahige B.
15 Jun 21
SC 13D
Tarrabain Alex
15 Jun 21
SC 13D
Byrne Joseph A.
15 Jun 21
SC 13D
Boswell Richard
15 Jun 21
4
de Lavenu Harold Andre Aubrey
4 Jun 21
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 148.15 k | 148.15 k | 148.15 k | 148.15 k | 148.15 k | 148.15 k |
Cash burn (monthly) | (no burn) | 5.47 k | 162.13 k | 235.78 k | 30.05 k | 49.23 k |
Cash used (since last report) | n/a | 98.19 k | 2.91 mm | 4.23 mm | 539.28 k | 883.48 k |
Cash remaining | n/a | 49.96 k | -2.76 mm | -4.08 mm | -391.13 k | -735.33 k |
Runway (months of cash) | n/a | 9.1 | -17.0 | -17.3 | -13.0 | -14.9 |
Institutional ownership, Q4 2021
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 2.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vectors Research Management | 2.00 | $0.00 |